Breast Cancer: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Breast cancer is the most common cancer in women worldwide, with approximately 2.3 million new cases annually and the leading cause of female cancer death in most countries. In the US, approximately 300,000 new cases are diagnosed each year; 1 in 8 American women will develop breast cancer in their lifetime. Men account for less than 1% of cases. Breast cancer is not a single disease: it comprises distinct molecular subtypes — Luminal A, Luminal B, HER2-enriched, and triple-negative — each with different biology, prognosis, and response to treatment. Modern staging (AJCC 8th edition) integrates tumor size, nodal involvement, distant metastases, tumor grade, hormone receptor and HER2 status, and genomic assay results (Oncotype DX) into a comprehensive prognostic framework. Breast Cancer: Causes, Symptoms, Diagnosis and Treatment is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Breast Cancer: Causes, Symptoms, Diagnosis and Treatment to help patients understand the condition, its causes, symptoms, and available treatment options.

BRCA1 and BRCA2 germline mutations cause approximately 10% of breast cancers and confer 45-72% lifetime risk; BRCA1-associated tumors are predominantly triple-negative, while BRCA2 mutations favor ER-positive cancers. Additional high-risk genes include PALB2, CHEK2, and ATM. Modifiable risk factors include obesity (postmenopausal — adipose estrogen production via aromatase), alcohol consumption, hormone replacement therapy (combined estrogen-progestagen), early menarche, late menopause, nulliparity, and prior chest radiation. Non-modifiable factors: female sex, increasing age, dense breast tissue, family history, and prior personal breast cancer or atypical hyperplasia. Most cases are sporadic, reflecting cumulative DNA damage in breast epithelial cells over time. The causes of Breast Cancer: Causes, Symptoms, Diagnosis and Treatment are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

The most common presenting symptom is a painless breast lump, but most breast lumps (80%) are benign. Skin changes including dimpling, puckering, redness, or peau d'orange (orange-peel appearance from dermal lymphatic obstruction) suggest underlying malignancy. Nipple changes — discharge (especially bloody or unilateral), retraction, or Paget disease (eczematoid nipple skin changes) — require investigation. Axillary lymphadenopathy may represent nodal metastasis from a primary too small to palpate. Inflammatory breast cancer (IBC) presents as rapid-onset erythema, warmth, swelling, and peau d'orange without a distinct palpable mass and must be diagnosed clinically — it is a clinical emergency requiring urgent oncology referral. Metastatic disease causes bone pain, dyspnea (pleural effusion), neurological symptoms, and hepatomegaly.

Triple assessment: clinical examination, mammography and/or ultrasound, and core needle biopsy for histology. MRI is used for high-risk surveillance, operative planning, and assessment of contralateral breast. Immunohistochemistry determines ER, PR, HER2 status, and Ki-67 index. AJCC 8th edition TNM staging integrates tumor size, nodal status, distant metastasis, tumor grade, receptor status, and Oncotype DX Recurrence Score. Oncotype DX guides chemotherapy decisions in ER+/HER2- early breast cancer. Germline BRCA1/2 testing is recommended per NICE/NCCN criteria. PET-CT or bone scan for staging in locally advanced or metastatic disease. CDH1 germline testing for lobular histology with family history of diffuse gastric cancer. Diagnosis of Breast Cancer: Causes, Symptoms, Diagnosis and Treatment typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Surgery ranges from breast-conserving lumpectomy (followed by whole-breast radiotherapy, equivalent survival to mastectomy) to mastectomy with reconstruction; sentinel lymph node biopsy is standard for axillary staging. ER+ breast cancer: 5-10 years endocrine therapy (tamoxifen premenopausal; aromatase inhibitors postmenopausal) plus CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for metastatic HR+/HER2- disease. HER2+ disease: neoadjuvant and adjuvant trastuzumab plus pertuzumab plus chemotherapy; T-DM1 for residual disease after neoadjuvant; trastuzumab deruxtecan (T-DXd) for metastatic HER2+. TNBC: pembrolizumab plus chemotherapy (neoadjuvant, KEYNOTE-522); adjuvant capecitabine for residual disease; olaparib for germline BRCA1/2-mutated metastatic. PARP inhibitors for BRCA-mutated HER2-negative metastatic disease. Treatment of Breast Cancer: Causes, Symptoms, Diagnosis and Treatment is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Breast cancer prognosis is highly dependent on stage, molecular subtype, and receptor status. Stage I breast cancer carries 5-year overall survival exceeding 99%; Stage II approximately 86-90%; Stage III approximately 72-80% with modern treatment; Stage IV (metastatic) approximately 28-30% 5-year overall survival, but highly variable by molecular subtype and treatment era. Hormone receptor-positive (ER+/PR+) HER2-negative breast cancer carries the best long-term prognosis — 10-year survival exceeds 80% for Stage I-II disease treated with surgery plus adjuvant endocrine therapy; CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) extend median progression-free survival in metastatic ER+ disease to approximately 24-36 months. Late recurrences are characteristic of ER-positive disease, occurring in approximately 20-25% of patients over 10-20 years — extended endocrine therapy (10 years vs 5 years) reduces this risk by approximately 25-30%. HER2-positive breast cancer: historically poor prognosis has been transformed by HER2-targeted therapy — 5-year survival for early HER2+ disease treated with trastuzumab-based regimens exceeds 85-90%. Trastuzumab deruxtecan (T-DXd) for metastatic HER2-positive disease achieves unprecedented responses with median OS exceeding 30 months in the DESTINY-Breast03 trial. Triple-negative breast cancer (TNBC): most aggressive subtype — 5-year survival approximately 65-77% for early-stage TNBC treated with neoadjuvant pembrolizumab plus chemotherapy (KEYNOTE-522: 5-year event-free survival 81.3% vs 72.3% for chemotherapy alone). BRCA1/2 germline mutation carriers with HER2-negative metastatic disease benefit from olaparib (PARP inhibitor) with median PFS of approximately 7 months versus 4.2 months for chemotherapy. The Oncotype DX Recurrence Score guides chemotherapy decisions in ER+ early-stage disease, improving survival optimization. Pathological complete response (pCR) after neoadjuvant therapy is the strongest surrogate predictor of long-term survival, particularly in HER2+ and TNBC subtypes.

Primary prevention for average-risk women: annual or biennial mammography screening from age 40-50 (per NCCN/ACS guidelines), limiting alcohol, maintaining healthy weight, regular physical activity (≥150 min/week), and minimizing postmenopausal HRT duration. High-risk women (BRCA1/2, prior LCIS or atypical hyperplasia, Tyrer-Cuzick lifetime risk >20%): annual mammography plus MRI, chemoprevention with tamoxifen (pre- or postmenopausal) or aromatase inhibitors (anastrozole, exemestane, postmenopausal) — each reduces ER-positive breast cancer incidence by approximately 50%. Risk-reducing bilateral mastectomy reduces BRCA1/2-associated breast cancer risk by over 90%. Risk-reducing salpingo-oophorectomy in BRCA carriers further reduces risk and ovarian cancer mortality.

Promptly consult a healthcare provider if you notice: a new breast lump or thickening that was not previously present; nipple discharge — especially if bloody, unilateral, or spontaneous; skin changes over the breast (dimpling, redness, puckering, or peau d'orange texture); nipple retraction or inversion that is new; changes in breast shape, size, or contour; swollen lymph nodes in the armpit; or breast pain that is focal, persistent, and unexplained. All new breast lumps require evaluation regardless of age. Women with a strong family history of breast or ovarian cancer should seek genetic counseling for BRCA testing. Any symptom suggesting inflammatory breast cancer — rapid breast redness and swelling — requires same-week specialist assessment.